secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001104659-25-008357
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee doses first patient in Part B of Phase 2 APEX trial for APG777 in atopic dermatitis
--------------------------------------------------------------------------------

- Part A enrolled 123 patients (exceeded ~110 target) randomized 2:1 APG777 vs placebo; >90% power for primary endpoint.
- Part A 16-week induction data expected mid-2025; maintenance data first half 2026; Part B 16-week data second half 2026.
- APG777 modeled to exceed lebrikizumab exposures by ~30–40% with ~70–90% fewer maintenance injections vs current therapies.
- Plans to initiate Phase 1b combo study of APG777 and APG990 (anti-OX40L) in AD in 2025 with readout in second half 2026.
- Expansion plans include Phase 1b/2b asthma trials in 2025 and Phase 2 EoE trial in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925008357/0001104659-25-008357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465925008357/tm255268d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-008357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer